AI Article Synopsis
- Bickerstaff's encephalitis is characterized by symptoms such as eye movement difficulties, lack of coordination, and altered consciousness, often linked to GQ1b antibodies in the bloodstream.
- A patient with this condition did not improve with traditional treatments like plasma exchange or intravenous immunoglobulin but showed recovery after receiving Rituximab, an anti-CD20 monoclonal antibody.
- The treatment led to a decrease in GQ1b antibodies in the serum and also detected GQ1b antibodies in the cerebrospinal fluid, suggesting important clinical and immune response insights.
Article Abstract
Bickerstaff's encephalitis is a syndrome of ophthalmoplegia, ataxia and impaired consciousness commonly associated with serum GQ1b antibodies. We describe a patient with seropositive Bickerstaff's encephalitis who did not respond either to plasma exchange or intravenous immunoglobulin but recovered following adjunct treatment with the anti-CD 20 monoclonal antibody, Rituximab. There was a concomitant reduction in serum GQ1b antibodies associated with improvement. Interestingly, GQ1b antibody was also detected in CSF. These findings have potentially significant clinical and immunopathological implications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jneuroim.2012.07.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!